Nootropic & Neurotropic Peptides

Nootropic peptides are a loosely defined class of peptide sequences investigated for effects on cognition, anxiety, and neuronal survival. The class spans ACTH-derived fragments (Semax), immunomodulatory analogs repurposed as anxiolytics (Selank), angiogenesis-pathway potentiators (Dihexa), and complex brain-derived peptide mixtures (Cerebrolysin), with Oxytocin studied for social cognition. What unifies the class is not a shared receptor but a shared objective: modulating central nervous system function with peptide structures. The clinical evidence base is unusually stratified, ranging from drugs registered for decades in Russia (Semax, Selank) to compounds with only animal data (Dihexa).

Semax is a synthetic ACTH(4-7) analog that upregulates BDNF expression and TrkB receptor signaling in the hippocampus and basal forebrain, alongside melanocortin receptor activity that distinguishes it from other cognitive peptides. Selank is a tuftsin analog that modulates GABA-A receptor function and suppresses stress-induced IL-6 elevation, producing anxiolytic effects in animal models without sedation. Dihexa is an N-hexanoic derivatized peptide that potentiates hepatocyte growth factor (HGF) binding to its receptor c-Met, driving synaptogenesis in hippocampal neuron cultures. Cerebrolysin is a porcine brain-derived hydrolysate containing multiple low-molecular-weight neurotrophic peptides proposed to mimic endogenous growth factor activity. Oxytocin acts at OXTR receptors in limbic circuits to modulate social salience and fear processing.

Semax is registered in Russia for stroke recovery, neuroprotection, and cognitive disorders, and Selank is registered there as an anxiolytic; neither has undergone Western-style Phase 3 development. Cerebrolysin is approved in several countries for stroke and dementia, though its evidence base remains contested in systematic reviews. Oxytocin is FDA-approved for obstetric indications, with intranasal social-cognition applications remaining investigational. Dihexa is preclinical only, with no completed human trials. Critically, the foundational 2014 study reporting Dihexa's synaptogenic potency (Benoist et al.) has been retracted and cannot be cited as valid evidence; the remaining preclinical literature is correspondingly thin.

Blood-brain barrier penetration is the class-defining methodological challenge. Intranasal delivery is the dominant route for Semax, Selank, and intranasal Oxytocin research, while Cerebrolysin requires parenteral administration due to its peptide complexity. Dihexa's claimed oral bioavailability is pharmacologically unusual for a peptide and warrants scrutiny in study design. Cognitive endpoint heterogeneity across animal and human studies complicates cross-compound comparison, and much of the Semax and Selank trial literature is published in Russian, limiting independent verification. Retraction status of cited synaptogenesis studies should be confirmed before relying on any Dihexa efficacy claim.